CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 82 enrolled
Drug / intervention
Furosemide +1 moredrug
Likely dose
Furosemide 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04752475
NCT04752475Phase 3Completed

Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)

Columbia University·interventional·Posted Feb 12, 2021·Updated Dec 13, 2024

In Brief

A Phase 3 clinical trial evaluating Furosemide and Placebo for Postpartum Pregnancy-Induced Hypertension and 3 related conditions. Completed, enrolled 82 participants across 1 site.

Detailed Summary

Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women. Secondary objectives: To evaluate whether oral furosemide administered to high-risk women after delivery can reduce the frequency of postpartum hypertensive episodes, the need for antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe maternal morbidity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 12, 2021
Enrollment StartOct 20, 2021
Primary CompletionApr 18, 2022
Study CompletionMay 28, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.4 years ago

Interventions

Furosemidedrug

Furosemide 20 mg pill taken daily for 5 days

Placeboother

Identical-appearing placebo pill taken daily for 5 days